Progress in systemic administration of adenovirus vector for cancer gene therapy
10.3781/j.issn.1000-7431.2017.55.377
- Author:
Jianhua CHEN
1
Author Information
1. State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine
- Publication Type:Journal Article
- Keywords:
Administration;
Antineoplastic agents;
Drug carriers;
Genetic therapy;
Intravenous;
Oncolytic viruses
- From:
Tumor
2017;37(12):1339-1343
- CountryChina
- Language:Chinese
-
Abstract:
Gene therapy has become a new cancer therapy model behind surgical excision, radiotherapy, chemotherapy and interventional therapy. The choice of proper carrier is very important in cancer gene therapy. Adenovirus is widely used as a vector carrier in cancer gene therapy. Gene-engineered oncolytic adenovirus (OncoAd) has the advantages including cancer cell-specific replication, infected cell destruction, and high expression of inserted therapeutic genes, so as to obtain the potent antitumor efficacy. Therefore, using OncoAd is considered to be an effective tumor therapy strategy. The systemic administration of intravenous delivery plays an important role in the treatment of advanced metastatic cancer. However, the delivery of OncoAd was limited to local injection in vivo in the past. Because the efficacy of intravenously administering OncoAd is compromised by non-specific sequestration in the liver and host immune response, while the non-viral vectors have the advantages of good biosafety and low immunogenicity, the combination of the two will be beneficial to the systemic administration of OncoAd. In this paper, the research strategies of OncoAd intravenous delivery for cancer gene therapy in recent years are reviewed, and the research progress in OncoAd combined with non-viral vector for cancer gene therapy is emphasized.
